NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Clinical Trials
22 trialsNCT07361133 2026-01-22
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Phase 2 Not yet recruiting
NCT07349225 2026-01-16
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
The Second Affiliated Hospital of Dalian Medical University
Phase 2 Not yet recruiting
NCT07321912 2026-01-08
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Not yet recruiting
NCT07258147 2025-12-02
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Phase 2 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07172412 2025-09-30
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07117877 2025-08-28
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07141771 2025-08-26
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Not yet recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07083375 2025-07-24
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT06648200 2024-10-18
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06497530 2024-07-12
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT06463171 2024-06-17
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06375109 2024-04-19
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
Phase 2 Not yet recruiting
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT06086288 2023-10-17
PANDORA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT05590572 2022-10-21
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting